NDSN — Nordson Corporation

Sentiment is genuinely constructive, not just polite: the 2026-08-19 Q3 print was a record quarter with revenue +10% YoY (~12% organic) and adjusted EPS of $3.25 versus ~$3.09 consensus, management raised FY26 guidance to $3.035-3.075B of sales and $11.80-12.00 of adjusted EPS, and total backlog is up 35% YoY with book-to-bill around 1.14x. Sell-side followed: DA Davidson went $345 to $375, Oppenheimer $335 to $370, KeyBanc $335 to $360, with only Baird staying Neutral at $351 (consensus target $360.20). The 2026-08-27 announcement of a 15% dividend hike to $0.94/quarter - the 63rd consecutive annual increase - reinforced the quality narrative. Price action confirms it: as of 2026-09-13 the stock is +9.11% over three months and +17.53% over six, though it has gone quiet near-term (-1.22% over one week, +1.03% over one month) and RSI at 49.64 shows the enthusiasm has cooled rather than broken.

This is an up-cycle inflection, not a fading story, and the sequence is clear. Revenue by quarter has gone $669.5M (Jan-2026) to $740.8M (Apr-2026) to $817.7M (Jul-2026) - a record - with YoY growth accelerating from +1.0% in the Oct-2025 quarter ($751.8M vs $744.5M) to +8.8% (Jan-2026), +8.5% (Apr-2026) and +10.3% (Jul-2026). Operating margin has expanded roughly 200bp YoY in each of the last three quarters: 24.9% vs 22.9% (Jan-2026), 26.6% vs 24.7% (Apr-2026), 27.3% vs 25.3% (Jul-2026), with TTM operating margin now 26.9% and gross margin 55.3%; the brief pegs EBITDA margins near a record ~32%. GAAP diluted EPS went $2.21 (Jul-2025) to $2.69 (Oct-2025) to $2.38 (Jan-2026) to $2.09 (Apr-2026) to $2.73 (Jul-2026). Two caveats worth flagging: the Jan-2026 quarter looks tax-flattered (net income $133.4M on $669.5M revenue, a 19.9% net margin, versus $117.3M on $740.8M revenue in Apr-2026, a 15.8% margin despite $30.8M more operating income), and the Apr-2026 GAAP dip to $2.09 is mostly amortization/timing rather than demand, since operating income still rose YoY. Cash is clean: TTM free cash flow is $728.5M and the accruals ratio of -1.62% as of 2026-07-31 means cash is running ahead of reported earnings, not behind.

Full-to-slightly-rich versus its own history, but not bubble territory. As of 2026-09-13, the $314.47 price is 31.7x trailing GAAP EPS of $9.965 versus a 5-year average P/E of 28.14x (a ~13% premium), and 5.88x sales versus a 5-year average P/S of 5.20x (also ~13% rich). Price/book is 5.36x, EV/EBITDA 20.4x, PEG 1.31, and the TTM FCF yield is roughly 4.2% ($728.5M FCF against $17.5B market cap). On forward numbers the picture improves materially: using the $11.893 next-FY consensus EPS (which matches company FY26 guidance of $11.80-12.00) the forward P/E is 26.4x, and on my ~$13.00 FY27 estimate it is 24.2x. So the honest read is that the market has already paid for the recovery - the question is whether 10% organic growth and record margins extend into FY27, not whether the stock is cheap.

This is not a case of the price discounting growth that hasn't shown up - the growth has already shown up (record Q3, +35% backlog, a raised guide), and the stock has been re-rated accordingly from a 52-week low of $220.47 to a high of $339.12. The risk therefore sits in the multiple, not the earnings. If FY27 guidance lands at or above the ~$13.00 adjusted EPS my model implies, the current price only carries ~24x forward and there is room toward the $345-375 analyst targets. If instead FY27 guidance comes in at only +5-8% - plausible if the electronics/advanced-packaging order wave normalizes - a de-rating to 22-24x forward puts the stock in the $285-310 zone on perfectly respectable absolute results. Practically: buy the earnings news, but don't buy the multiple expansion twice.

As of 2026-09-13, RSI(14) was 49.64 - dead neutral, neither overbought nor oversold - with the price 1.7% below its 20-day SMA but 2.8% above the 50-day and 11.97% above the 200-day, which is a textbook consolidation inside an intact intermediate-term uptrend. The 52-week range is $220.47-$339.12, so the stock is about 7% off its high, and trailing returns are -1.22% (1 week), +1.03% (1 month), +9.11% (3 months) and +17.53% (6 months). There is no technical urgency here: the chart is neither an oversold entry nor an overbought chase. A pullback toward the 50-day SMA (roughly $306) or the $290-300 shelf would be a materially better risk/reward entry than $314, and a decisive break above $339 on strong volume would confirm the next leg.

• Electronics/AI capital-spending supercycle: advanced semiconductor packaging, panel-level packaging and AI infrastructure hardware are driving Nordson's Advanced Technology Solutions segment, which is why the ASYMTEK Vantage XL launch at SEMICON Taiwan (2026-09-05) matters more than a typical product refresh.
• Industrial capital-spending cycle: traditional Industrial Precision Solutions end markets remain mixed with a slow cyclical recovery, while Medical and Fluid Solutions compounds steadily - so roughly two-thirds of the portfolio is stable and one-third is carrying the growth story.
• Rates and cost of capital: moderating inflation and easing debt costs help a levered acquirer (debt/equity 0.555, long-term debt $1.529B), and the new commercial paper program added during the quarter gives cheap, flexible funding for M&A.
• Tariffs and trade friction: Nordson sells into a diverse global manufacturing base with significant non-US revenue, so tariffs affect both equipment demand from customers and input costs, and FX translation cuts both ways on reported results.
• Serial-acquirer M&A environment: with net debt/EBITDA around 1.5x and strong free cash flow, Nordson has real capacity to buy growth - which is a tailwind if multiples paid are disciplined and a risk if they are not.

• Q4/FY2026 earnings and initial FY2027 guidance, expected late November or early December 2026 - the single biggest re-rating event, since it will show whether the +35% backlog converts and what growth management will underwrite for FY27.
• Backlog conversion and order-entry trends: book-to-bill near 1.14x needs to hold; a slip toward or below 1.0x would be the first hard signal that the advanced-packaging/electronics demand wave is normalizing.
• Ramp of the ASYMTEK Vantage XL and other ATS products into AI hardware and automotive electrification applications, which is the highest-incremental-margin growth vector in the portfolio.
• Continued 15%-style dividend increases and possible buyback acceleration, funded by ~$728M of TTM free cash flow and a newly established commercial paper program.
• Any announced acquisition - the balance sheet supports one, and deal multiples versus Nordson's own 5.36x P/B will be the tell on capital-allocation discipline.

• Multiple compression: at 31.7x trailing GAAP earnings versus a 28.1x 5-year average, a return to the historical multiple alone implies roughly $280 per share even if earnings hit plan - the valuation is the dominant risk, not the business.
• Cyclicality in semiconductor/electronics capital spending: ATS is both the growth engine and the most cyclical segment, and the company is currently posting record revenue with record ~32% EBITDA margins - i.e., the trailing numbers being scored are peak-ish, not trough.
• GAAP versus adjusted divergence: roughly $2.00 per year of acquisition-amortization separates adjusted EPS ($3.25 in Q3 FY26) from GAAP EPS ($2.73), so headline beats can mask a lower-quality reported number.
• Industrial Precision Solutions softness and tariff/trade friction: a slow general-manufacturing recovery and any escalation in trade barriers would hit the largest, least-cyclically-favored part of the portfolio.
• Order lumpiness and customer concentration in semiconductor and medical OEM channels, where a handful of large orders can swing a quarter in either direction.
• Capital allocation: ROIC of 10.7% is structurally held down by a goodwill-heavy, serial-acquirer balance sheet, so the return on the next deal matters more than the last one.

Nordson is a genuinely high-quality, cash-generative industrial machinery franchise in the middle of a real up-cycle: record Q3 FY26 revenue of $817.7M (+10.3% YoY), roughly 200bp of YoY operating-margin expansion for three consecutive quarters, 55.3% gross margins, $728M of TTM free cash flow at a ~4.2% yield, a 63-year dividend-increase streak, and net debt/EBITDA around 1.5x. The problem is not the company, it is the price: at $314.47 as of 2026-09-13 the stock trades at 31.7x trailing and ~26x forward earnings, above its own 5-year averages, and the trailing results it is being valued on are record-margin, cycle-peak numbers. I would want either a pullback to the high-$280s/low-$300s or a credible FY27 guide showing that the +35% backlog converts into sustained double-digit growth before committing new money at these levels.

I used a forward P/E approach on adjusted earnings: blending FY26 consensus adjusted EPS of $11.893 (which matches company guidance of $11.80-12.00, with Q4 FY26 implied at ~$3.18 after $8.72 of adjusted EPS in the first three quarters) with my ~$13.00 FY27 estimate implied by roughly 9% growth off the +35% backlog and 1.14x book-to-bill, gives a next-twelve-month adjusted EPS of about $12.55. I applied a 25.5x multiple - a premium to ITW/Graco-type industrial peers at ~22-24x for Nordson's 55.3% gross margin, 26.9% operating margin, negative accruals and 63-year dividend record, but a discount to the 31.7x trailing GAAP multiple it commands today - yielding about $321. Cross-checks corroborate: that price is a 4.1% free-cash-flow yield on $728M of TTM FCF and roughly 20x EV/EBITDA on ~$930M of TTM EBITDA, both consistent with a fairly-valued quality industrial, and both below the $360.20 sell-side consensus target, which implies a richer ~28x on FY27 earnings than I am willing to underwrite at this point in the cycle.